ENTA - Company ID 0001177648
The table below shows ENANTA PHARMACEUTICALS INC's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q4 2025 | Q4 2024 | Q4 2023 | Q4 2022 | Q4 2021 | Q4 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$11.70M | -$16.80M | -$24.99M | -$35.64M | -$13.27M | -$14.89M |
| Capital expenditure | $143.00K | $8.74M | $787.00K | $3.16M | $363.00K | $188.00K |
| Investing cash flow | -$47.30M | $68.90M | -$13.12M | $33.57M | $45.50M | -$17.45M |
| Dividends paid | - | - | - |
ENANTA PHARMACEUTICALS INC reported operating cash flow of -$19.27M for fiscal year 2025. That is up 75.5% from -$78.76M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $35.81M (FY 2016) to -$19.27M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $64.14M | -$4.99M | -$7.35M | $301.00K | $9.63M | $299.00K |